Abortion
Almeida backtracks and denies post-abortion syndrome existence
October 03, 2025 Hoton da AI ya samar
Madrid's mayor, José Luis Martínez-Almeida, has backtracked on his stance, now stating that post-abortion syndrome does not exist as a recognized scientific category. This contrasts with support from Spanish bishops and parties like Vox and PP for the concept, despite clear scientific denial. The debate arises amid political discussions on abortion in Spain.
Supreme Court upholds FDA approval of mifepristone
The U.S. Supreme Court unanimously ruled on June 13, 2024, that the FDA's approval of the abortion pill mifepristone is valid and remains in effect. The decision dismissed challenges from anti-abortion groups, affirming the agency's regulatory authority. This ruling ensures continued access to medication abortion, which accounts for more than half of U.S. abortions.
Senator Hawley criticizes FDA approval of new abortion drug
Republican Senator Josh Hawley from Missouri has sharply criticized the Food and Drug Administration for approving a new abortion drug, raising concerns about women's safety and the agency's trustworthiness. In a letter to FDA Commissioner Robert Califf, Hawley accused the agency of prioritizing politics over science. The move highlights ongoing debates over abortion access and regulatory oversight.
Federal judge blocks Idaho abortion ban in emergencies
October 03, 2025 An Ruwaito ta hanyar AI
A federal judge in Idaho has ruled that the state's strict abortion ban cannot be enforced in medical emergencies, providing temporary relief to healthcare providers. The decision addresses concerns that the law endangers women by creating uncertainty in critical situations. This ruling comes amid ongoing legal challenges to post-Roe v. Wade restrictions.
Federal judge blocks expanded access to abortion pill mifepristone
October 03, 2025 An Ruwaito ta hanyar AI
A federal judge in Texas has issued a ruling limiting the FDA's approval of mifepristone, the primary drug used in medication abortions. The decision revives a long-standing lawsuit challenging the drug's safety and regulatory process. This comes amid ongoing legal battles over abortion access following the Supreme Court's overturning of Roe v. Wade.